Literature DB >> 16718690

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.

Edgar Meinl1, Markus Krumbholz, Reinhard Hohlfeld.   

Abstract

B cells have long played an enigmatic role in the scenario of multiple sclerosis pathogenesis. This review summarizes recent progress in our understanding of B-cell trafficking, survival, and differentiation in the central nervous system (CNS). We propose four possible routes of intrathecal immunoglobulin-producing cells. The inflammatory CNS provides a unique, B-cell-friendly environment, in which B lineage cells, notably long-lived plasma cells, can survive for many years, perhaps even for a lifetime. These new findings offer a plausible explanation for the notorious persistence and stability of cerebrospinal fluid oligoclonal bands. Furthermore, we highlight similarities and differences of intrathecal immunoglobulin production in multiple sclerosis patients and patients with other CNS inflammatory conditions. Finally, we outline the possibly double-edged effects of B cells and immunoglobulin in the CNS and discuss various therapeutic strategies for targeting the B-cell response. Ann Neurol 2006;59:880-892.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16718690     DOI: 10.1002/ana.20890

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  80 in total

1.  Antigen microarrays identify CNS-produced autoantibodies in RRMS.

Authors:  F J Quintana; M F Farez; G Izquierdo; M Lucas; I R Cohen; H L Weiner
Journal:  Neurology       Date:  2012-01-18       Impact factor: 9.910

Review 2.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

3.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

4.  Switch-associated protein 70 antibodies in multiple sclerosis: relationship between increased serum levels and clinical relapse.

Authors:  Ece Erdağ; Erdem Tüzün; Elif Uğurel; Filiz Cavuş; Elçin Sehitoğlu; Murat Giriş; Burçak Vural; Mefküre Eraksoy; Gülşen Akman-Demir
Journal:  Inflamm Res       Date:  2012-05-22       Impact factor: 4.575

5.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

6.  Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.

Authors:  Andrew Chan; De-Hyung Lee; Ralf Linker; Alexander Mohr; Klaus V Toyka; Ralf Gold
Journal:  J Neurol       Date:  2007-08-27       Impact factor: 4.849

7.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Dennis Bourdette; Vijayshree Yadav
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

8.  [B lymphocytes: a new "target" in treatment for multiple sclerosis].

Authors:  R Hohlfeld
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

9.  How relevant are GFAP autoantibodies in autism and Tourette Syndrome?

Authors:  Nikki J Kirkman; Jane E Libbey; Thayne L Sweeten; Hilary H Coon; Judith N Miller; Edward K Stevenson; Janet E Lainhart; William M McMahon; Robert S Fujinami
Journal:  J Autism Dev Disord       Date:  2007-06-20

10.  Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis.

Authors:  Talibah U Metcalf; Victoria K Baxter; Voraphoj Nilaratanakul; Diane E Griffin
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.